Table 1

Characteristics of Participants

Total

Phase 2 - treatment

Phase 2 - placebo


Total Participants

77

26

15

Male

69

24

14

Female

8

2

1

Age (years)

6.3

6.7

6.5

Diagnosis

95% autism, 3% PDD/NOS, 3% Asperger's

96% Autism, 4% Aspergers

100% Autism


Adams et al. BMC Clinical Pharmacology 2009 9:16   doi:10.1186/1472-6904-9-16

Open Data